Celldex Therapeutics
CLDX
180 hedge funds and large institutions have $1.48B invested in Celldex Therapeutics in 2025 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 75 increasing their positions, 42 reducing their positions, and 28 closing their positions.
79% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 42
36% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 28
11% more capital invested
Capital invested by funds: $1.34B → $1.48B (+$143M)
5% more funds holding
Funds holding: 171 → 180 (+9)
1.99% less ownership
Funds ownership: 110.92% → 108.93% (-2%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
40% less call options, than puts
Call options by funds: $3.21M | Put options by funds: $5.37M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
+$30.2M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
+$11.7M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$8.13M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$7.93M |
| 5 |
SBH
Segall Bryant & Hamill
Chicago,
Illinois
|
+$7.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$60.8M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$46.7M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$12.2M |
| 4 |
State Street
Boston,
Massachusetts
|
-$7.8M |
| 5 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$7.77M |
CLDX Hedge Fund Activity: Q2 2025 in Review
180 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q2 2025, worth a combined $1.48B — up 11% from $1.34B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new CLDX positions and 28 closed out — a net gain of 10 holders — while 75 added to existing stakes and 42 trimmed.
The largest buyer was Vestal Point Capital, adding an estimated $30.2M. The largest seller was Wellington Management Group, cutting an estimated $60.8M.
- 180 institutional investors held Celldex Therapeutics (CLDX) as of Q2 2025, up from 171 in Q1 2025.
- Funds reported $1.48B of Celldex Therapeutics stock for Q2 2025, up 11% quarter-over-quarter.
- 38 funds opened new Celldex Therapeutics positions in Q2 2025 and 28 closed out, a net change of +10 holders.
- The largest Celldex Therapeutics buyer in Q2 2025 was Vestal Point Capital, an estimated $30.2M added.
- The largest Celldex Therapeutics seller in Q2 2025 was Wellington Management Group, an estimated $60.8M sold.
Based on aggregated 13F filings for Q2 2025.